Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 10.11
-0.04 (-0.39%)
Jun 10, 2026, 2:14 PM HKT
Ascletis Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 |
Depreciation & Amortization | 16.88 | 18.86 | 16.78 | 28.4 | 27.83 |
Other Amortization | 0.36 | 1.89 | 3.42 | 2.11 | 2.14 |
Loss (Gain) From Sale of Assets | -26.51 | -4.36 | -0.09 | 0 | - |
Asset Writedown & Restructuring Costs | - | 10.58 | - | 55.19 | - |
Loss (Gain) From Sale of Investments | -0.87 | 23.6 | - | - | - |
Loss (Gain) on Equity Investments | - | -15.87 | -40.31 | 22.89 | 17.88 |
Stock-Based Compensation | 7.63 | 3 | 1.33 | 3.19 | 7.13 |
Provision & Write-off of Bad Debts | - | -0 | -0 | -0.01 | 0.01 |
Other Operating Activities | -59.15 | -92.13 | -94.67 | -33.2 | 7.27 |
Change in Accounts Receivable | -0.07 | 5.28 | 18.44 | 29.74 | -26.99 |
Change in Inventory | 2.46 | -3.6 | -8.05 | -12.84 | -5.07 |
Change in Accounts Payable | 1.31 | -0.62 | -2.49 | 2.08 | 0.12 |
Change in Unearned Revenue | -1.59 | -1.59 | -1.59 | -1.59 | -2.61 |
Change in Other Net Operating Assets | 2.66 | 14.31 | 28.14 | 16.41 | 24.37 |
Operating Cash Flow | -416.78 | -341.58 | -223.8 | -202.46 | -146.93 |
Capital Expenditures | -1.64 | -2.1 | -6.21 | -7.07 | -4.97 |
Sale of Property, Plant & Equipment | 0.04 | - | 0.12 | - | - |
Sale (Purchase) of Intangibles | -0.33 | -0.05 | -12.95 | -7.24 | -2.23 |
Investment in Securities | 579.81 | 853.84 | 160.73 | -1,137 | -269.78 |
Other Investing Activities | 84.3 | 127.22 | 87.78 | 3.32 | 2.48 |
Investing Cash Flow | 662.18 | 978.91 | 229.48 | -1,148 | -274.49 |
Long-Term Debt Repaid | -6.46 | -4.73 | -2.39 | -2.22 | -2.28 |
Net Debt Issued (Repaid) | -6.46 | -4.73 | -2.39 | -2.22 | -2.28 |
Issuance of Common Stock | 433.43 | - | - | 0.96 | - |
Repurchase of Common Stock | -81.58 | -98.53 | -78.96 | - | -28.69 |
Other Financing Activities | -0.16 | -0.24 | -0.14 | -0.16 | -0.13 |
Financing Cash Flow | 345.23 | -103.51 | -81.5 | -1.42 | -31.1 |
Foreign Exchange Rate Adjustments | -11.44 | 0.39 | 2.16 | 28.62 | -30.57 |
Net Cash Flow | 579.19 | 534.21 | -73.65 | -1,324 | -483.09 |
Free Cash Flow | -418.42 | -343.67 | -230.01 | -209.53 | -151.9 |
Free Cash Flow Margin | -20632.10% | -26786.75% | -406.40% | -387.38% | -197.59% |
Free Cash Flow Per Share | -0.43 | -0.34 | -0.21 | -0.19 | -0.14 |
Cash Interest Paid | 0.16 | 0.24 | 0.14 | 0.16 | 0.13 |
Levered Free Cash Flow | -300.66 | -208.35 | -131.07 | -114.01 | -111.93 |
Unlevered Free Cash Flow | -300.55 | -208.2 | -130.98 | -113.91 | -111.86 |
Change in Working Capital | 4.77 | 13.79 | 34.45 | 33.81 | -10.18 |